EMAIL THIS PAGE TO A FRIEND

Molecular pharmacology

Multiple modes of ryanodine receptor 2 inhibition by flecainide.


PMID 25274603

Abstract

Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden cardiac death due to mutations in cardiac ryanodine receptors (RyR2), calsequestrin, or calmodulin. Flecainide, a class I antiarrhythmic drug, inhibits Na(+) and RyR2 channels and prevents CPVT. The purpose of this study is to identify inhibitory mechanisms of flecainide on RyR2. RyR2 were isolated from sheep heart, incorporated into lipid bilayers, and investigated by single-channel recording under various activating conditions, including the presence of cytoplasmic ATP (2 mM) and a range of cytoplasmic [Ca(2+)], [Mg(2+)], pH, and [caffeine]. Flecainide applied to either the cytoplasmic or luminal sides of the membrane inhibited RyR2 by two distinct modes: 1) a fast block consisting of brief substate and closed events with a mean duration of ∼1 ms, and 2) a slow block consisting of closed events with a mean duration of ∼1 second. Both inhibition modes were alleviated by increasing cytoplasmic pH from 7.4 to 9.5 but were unaffected by luminal pH. The slow block was potentiated in RyR2 channels that had relatively low open probability, whereas the fast block was unaffected by RyR2 activation. These results show that these two modes are independent mechanisms for RyR2 inhibition, both having a cytoplasmic site of action. The slow mode is a closed-channel block, whereas the fast mode blocks RyR2 in the open state. At diastolic cytoplasmic [Ca(2+)] (100 nM), flecainide possesses an additional inhibitory mechanism that reduces RyR2 burst duration. Hence, multiple modes of action underlie RyR2 inhibition by flecainide.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

F-017
(±)-Flecainide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
C17H20F6N2O3
14510
1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, ≥96.0% (HPLC)
C22H24N2O10
A4926
1,2-Bis(2-Aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, 98%
C22H24N2O10
93784
Caffeine, PharmaGrade, EP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production
C8H10N4O2
C0750
Caffeine, powder, ReagentPlus®
C8H10N4O2
C8960
Caffeine, BioXtra
C8H10N4O2
C1778
Caffeine, Sigma Reference Standard, vial of 250 mg
C8H10N4O2
C0100000
Caffeine, European Pharmacopoeia (EP) Reference Standard
C8H10N4O2
C7731
Caffeine, meets USP testing specifications, anhydrous
C8H10N4O2
1085003
Caffeine, United States Pharmacopeia (USP) Reference Standard
C8H10N4O2
PHR1009
Caffeine, Pharmaceutical Secondary Standard; Certified Reference Material
C8H10N4O2
56396
Caffeine, certified reference material, TraceCERT®
C8H10N4O2
05-0370
Caffeine, SAJ special grade, ≥98.5%
C8H10N4O2
Y0000787
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
C8H10N4O2
1086006
Caffeine melting point standard, United States Pharmacopeia (USP) Reference Standard
C8H10N4O2
PHR1095
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
C8H10N4O2
21049
Calcium standard for AAS, analytical standard, 1.000 g/L Ca+2 in hydrochloric acid, traceable to BAM
CaCl2
239240
Cesium, ingot, ≥99.95% trace metals basis
Cs
F0120000
Flecainide acetate, European Pharmacopoeia (EP) Reference Standard
C17H20F6N2O3 · C2H4O2
F6777
Flecainide acetate salt
C17H20F6N2O3 · C2H4O2
41019
Melting point standard 235-237°C, analytical standard
C8H10N4O2
75035
Mettler-Toledo Calibration substance ME 18872, Caffeine, analytical standard, for the calibration of the thermosystem 900, traceable to primary standards (LGC)
C8H10N4O2